Compare PayPal Holdings, Inc. (PYPL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? PayPal Holdings, Inc. trades at $52.27 (market cap $45.49B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: PayPal Holdings, Inc. is far larger — about 24.5× Recursion Pharmaceuticals Inc's market cap, and PayPal Holdings, Inc. pays a 1.05% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PYPL | RXRX | |
|---|---|---|
Market Cap | $45.49B | $1.86B |
Sector | Financials | Health |
52-Week High | $76.13 | $6.79 |
52-Week Low | $39.08 | $2.84 |
Enterprise Value | $47.64B | $1.38B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $53.18, down 3.24% on the day, reflecting recent volatility amid takeover speculation collapse and restructuring efforts. The stock shows bearish technical signals with key support at $51, while fundamentals remain solid with a P/E of 10.05, net income margin of 14.36%, and consistent revenue growth to $33.17B in 2025. Recent news highlights a strategic shift under new CEO Enrique Lores, targeting $1.5B in savings and expanding beyond branded checkout.
The outlook is mixed; valuation appears attractive with a consensus price target of $59.61, but near-term risks include execution of the turnaround plan and competitive pressures. Investor sentiment is cautious with 60% analyst hold ratings, though strong cash flow and dividend initiation provide stability. Upside depends on successful cost savings and new growth initiatives offsetting market skepticism.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
